The statin puzzle: A genetic key to dementia prevention in kidney patients?
A novel study emulating a clinical trial using UK Biobank data has applied causal machine learning to investigate the inconsistent link between statins and dementia. Analyzing over 18,000 participants, researchers found the overall effect on all-cause dementia risk was negligible. However, by using an algorithm to detect heterogeneous treatment effects, they identified a crucial subgroup: individuals with a high genetic predisposition to Alzheimer’s disease, specifically based on a polygenic risk score that excludes the well-known APOE gene. For these genetically susceptible individuals, initiating statin therapy was associated with a significant reduction in the risk of both all-cause dementia and Alzheimer’s disease.
Why it might matter to you: For nephrologists managing patients with chronic kidney disease, who frequently have comorbid cardiovascular disease and a heightened risk of cognitive decline, this research offers a more nuanced framework for statin use. It suggests that genetic profiling, particularly for non-APOE Alzheimer’s risk, could help stratify which patients are most likely to derive cognitive benefit from these commonly prescribed medications. This precision medicine approach could inform more personalized risk-benefit discussions, especially in older CKD populations where polypharmacy and competing risks are major clinical considerations.
Source →Stay curious. Stay informed — with Science Briefing.
Always double check the original article for accuracy.
